Skip to main
EXAS
EXAS logo

Exact Sciences (EXAS) Stock Forecast & Price Target

Exact Sciences (EXAS) Analyst Ratings

Based on 36 analyst ratings
Buy
Strong Buy 44%
Buy 39%
Hold 14%
Sell 0%
Strong Sell 3%

Bulls say

Exact Sciences is poised for significant market growth in the cancer screening sector due to an under-screened patient population and expansion into the 45-49 age demographic, leading to increased revenue and repeat orders. The launch of Cologuard Plus, which offers heightened accuracy and higher Medicare pricing, alongside a robust sales organization, positions Exact Sciences favorably to achieve or surpass near-term financial targets. Furthermore, the company continues to benefit from a strong portfolio of best-in-class diagnostic products and possesses ample room for growth, supported by industry-leading margins and profitability in the near to medium term.

Bears say

Exact Sciences has demonstrated mixed financial performance, finishing fiscal year 2024 with results slightly below initial guidance despite a positive surprise in 4Q revenue. The company faces potential regulatory surprises that could adversely affect revenue while also inflating operational costs, raising concerns about compliance risks. Furthermore, the overall downward trend in reimbursement for cancer screening could pose long-term challenges, creating uncertainty around the company’s future revenue sustainability.

Exact Sciences (EXAS) has been analyzed by 36 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 39% recommend Buy, 14% suggest Holding, 0% advise Selling, and 3% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exact Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exact Sciences (EXAS) Forecast

Analysts have given Exact Sciences (EXAS) a Buy based on their latest research and market trends.

According to 36 analysts, Exact Sciences (EXAS) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exact Sciences (EXAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.